Skip to content

Single Center Experience Over a Decade in Living Donor Liver Transplantation for Egyptian Patients With Hepatocellular Carcinoma: Stretching the Limits

Single Center Experience Over a Decade in Living Donor Liver Transplantation for Egyptian Patients With Hepatocellular Carcinoma: Stretching the Limits

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01937286
Enrollment
590
Registered
2013-09-09
Start date
2002-01-31
Completion date
2012-04-30
Last updated
2013-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrence of HCC After LDLT

Keywords

LDLT,HCC, Microvascular invasion

Brief summary

Within community with high incidence of HCC, stretching the limits could be justified based on tumor characters and its biological behavior

Detailed description

590 Egyptian patients underwent LDLT; of them, 172 (32%) patients were transplanted for HCC. Twenty six cases (15.1%) were excluded due to early postoperative mortality (n=22) or due to non HCC related mortality (n=4). One hundred forty six patients were retrospectively reviewed to determine prognostic factors for recurrence.

Interventions

None listed

Sponsors

Ain Shams University
Lead SponsorOTHER

Study design

Observational model
CASE_CROSSOVER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 62 Years
Healthy volunteers
No

Inclusion criteria

* Egyptien Patients with HCC * Patients within Milan Criteria * Patients beyond Milan criteria are selected on a case by case basis until 2005. From 2005 , patients beyond Milan criteria are subjected to down staging protocol and then reassessed (pre transplantation local ablative therapy either with RFA or TACE according to the size and the site of the lesion and we wait for 12 weeks after ablation ,only those with well ablated lesions, decreased AFP and no denovo lesions were transplanted).

Exclusion criteria

* • Evidence of macro vascular invasion by CT portography and/or US duplex. * Metastatic HCC * General contraindications for LT (ongoing sepsis, other major co morbidities,…). * Early postoperative mortality (first1 month). * Post transplant mortality during the period of follow up due to any cause other than recurrent HCC (e.g. sepsis, rejection, cardiological or cerebrovascular complications…)

Design outcomes

Primary

MeasureTime frame
Recurrence of Hepatocellular carcinoma after LDLTat least 6 months

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026